- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06592755
Single-Incision Gasless Endoscopic Total Thyroidectomy Via Subclavian Approach Versus Open Surgery for PTC
September 29, 2024 updated by: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Single-Incision Gasless Endoscopic Total Thyroidectomy Via Subclavian Approach Versus Open Surgery for Papillary Thyroid Carcinoma
Historically, performing a contralateral thyroid lobectomy and lymph node dissection via the subclavian approach was considered challenging.
This study aimed to evaluate the safety and feasibility of single-incision gasless endoscopic total thyroidectomy and central compartment neck dissection via the subclavian approach (SCA) in comparison to conventional open surgery for the treatment of papillary thyroid carcinoma (PTC) retrospectively.
Study Overview
Status
Recruiting
Conditions
Detailed Description
Historically, performing a contralateral thyroid lobectomy and lymph node dissection via the subclavian approach was considered challenging.
This study aimed to evaluate the safety and feasibility of single-incision gasless endoscopic total thyroidectomy and central compartment neck dissection via the subclavian approach (SCA) in comparison to conventional open surgery for the treatment of papillary thyroid carcinoma (PTC) retrospectively.
Study Type
Observational
Enrollment (Estimated)
120
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lin
- Phone Number: 0086-020-34071439
- Email: linpliang3@mail.sysu.edu.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Recruiting
- Sun Yat-sen Memorial Hospital
-
Contact:
- Lin
- Phone Number: 0086-020-34071439
- Email: linpliang3@mail.sysu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The patients, who were diagnosed with papillary thyroid carcinoma at our center, chose to undergo either single-incision, gasless endoscopic total thyroidectomy with central compartment neck dissection via the subclavian approach or conventional open surgery.
Description
Inclusion Criteria:
- (1) thyroid neoplasm <3.0 cm;
- (2) well differentiated papillary thyroid carcinoma.
Exclusion Criteria:
- (1) extrathyroidal extensions estimated in ultrasonography scan;
- (2) enlarged lymph nodes in lateral neck compartment on palpation, or US scan;
- (3) suspected distant metastases;
- (4) previous history of neck radiation therapy and/or surgery.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
the Subclavian Approach group
The patients chose to undergo total thyroidectomy and central compartment neck dissection via the single-incision subclavian approach.
|
The included patients chose to undergo single-incision, gasless endoscopic total thyroidectomy with central compartment neck dissection via the subclavian approach based on patients preference.
|
|
the conventional open surgery group
The patients chose to undergo total thyroidectomy and central compartment neck dissection via the conventional open surgery approach.
|
These patients chose to undergo total thyroidectomy with central compartment neck dissection via conventional open surgery based on patients preference.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the disease-free survival
Time Frame: up to 24 months
|
The disease-free survival refers to the probability of survival without any biologic, structural, or functional events.
|
up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 20, 2024
Primary Completion (Estimated)
September 30, 2024
Study Completion (Estimated)
September 30, 2024
Study Registration Dates
First Submitted
September 5, 2024
First Submitted That Met QC Criteria
September 10, 2024
First Posted (Actual)
September 19, 2024
Study Record Updates
Last Update Posted (Actual)
October 1, 2024
Last Update Submitted That Met QC Criteria
September 29, 2024
Last Verified
September 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SYSKY-2023-1124-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Papillary Thyroid Carcinoma
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Gland Carcinoma | Stage I Thyroid Gland Papillary Carcinoma | Stage II Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Stage IV Thyroid Gland Papillary CarcinomaUnited States, Canada
-
National Cancer Institute (NCI)ExelixisCompletedRecurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage I Thyroid Gland Papillary Carcinoma | Stage II Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Stage I Thyroid Gland... and other conditionsUnited States
-
Grupo Espanol de Tumores NeuroendocrinosMFARTerminatedMetastatic Thyroid Cancer | Metastatic Thyroid Papillary Carcinoma | Metastatic Thyroid Follicular CarcinomaSpain
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Gland Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Stage IV Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Follicular Carcinoma | Stage IV Thyroid Gland Follicular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedRefractory Differentiated Thyroid Gland Carcinoma | Unresectable Thyroid Gland Carcinoma | Refractory Thyroid Gland Papillary Carcinoma | Refractory Thyroid Gland Follicular Carcinoma | Refractory Thyroid Gland Hurthle Cell CarcinomaUnited States, Canada
-
National Cancer Institute (NCI)Active, not recruitingPoorly Differentiated Thyroid Gland Carcinoma | Refractory Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Differentiated Thyroid Gland Carcinoma | Thyroid... and other conditionsUnited States
-
The First Affiliated Hospital of Xiamen UniversityCompletedRefractory Thyroid Gland Carcinoma | Refractory Thyroid Gland Papillary Carcinoma | Refractory Thyroid Gland Follicular Carcinoma | Refractory Thyroid Gland Hurthle Cell CarcinomaChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)CompletedPoorly Differentiated Thyroid Gland Carcinoma | Recurrent Differentiated Thyroid Gland Carcinoma | Columnar Cell Variant Thyroid Gland Papillary Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Metastatic Thyroid Gland Follicular Carcinoma | Metastatic Thyroid Gland Papillary... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)CompletedRecurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid Gland Papillary Carcinoma AJCC... and other conditionsUnited States
-
University Health Network, TorontoUniversity of British Columbia; Canadian Institutes of Health Research (CIHR); CHU de Quebec-Universite Laval and other collaboratorsActive, not recruitingPapillary Thyroid Carcinoma | Papillary Thyroid Cancer | Papillary Microcarcinoma of the ThyroidCanada
Clinical Trials on single-incision, gasless endoscopic total thyroidectomy with central compartment neck dissection
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruitingThyroid CancerFrance, Guadeloupe, Reunion
-
Leonardo RossiNot yet recruitingPapillary Thyroid Carcinoma | Thyroidectomy | Central Compartment Neck Dissction | Thyroid Lobectomy
-
Jagiellonian UniversityCompleted
-
National Cancer Institute (NCI)TerminatedThyroid Cancer | Low-risk Papillary Thyroid Cancer | Endocrine MalignancyUnited States
-
Bassem Mohamed SiedaUnknownPapillary Thyroid CarcinomaEgypt
-
Fujian Medical UniversityRecruitingThyroid Neoplasms | Carcinoma, PapillaryChina